SEC-sourced researchBeta

KURA

Kura Oncology, Inc.

US markets

Data passport

CIK: 0001422143
Exchange: Nasdaq
Business activity: — · SIC 2834
Financial inputs: 6/6
Filing date: Sep 29, 2026
SEC registry record: Operating company

Last updated: Oct 5, 2026, 10:03 PM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

KURA · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	0.0000	Mar 5, 2026
December 2024	53,883,000.0000	Mar 5, 2026
December 2025	67,482,000.0000	Mar 5, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	67,482,000.0000	-278,666,000.0000	-64,058,000.0000	738,363,000.0000	564,228,000.0000	Mar 5, 2026
December 2024	53,883,000.0000	-173,983,000.0000	134,317,000.0000	760,159,000.0000	346,519,000.0000	Mar 5, 2026
December 2023	0.0000	-152,631,000.0000	-124,824,000.0000	—	—	Mar 5, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$67.48M	December 2025	Mar 5, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$53.88M	December 2024	Mar 5, 2026	10-K
Net incomeNetIncomeLoss	-$278.67M	December 2025	Mar 5, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$64.06M	December 2025	Mar 5, 2026	10-K
Total assetsAssets	$738.36M	December 2025	Mar 5, 2026	10-K
Total liabilitiesLiabilities	$564.23M	December 2025	Mar 5, 2026	10-K

New filings

Explore methodology ↗